<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04575285</url>
  </required_header>
  <id_info>
    <org_study_id>TMS Depression</org_study_id>
    <nct_id>NCT04575285</nct_id>
  </id_info>
  <brief_title>Using EEG to Predict Depression Treatment Response to rTMS in Patients With Major Depression</brief_title>
  <official_title>Using EEG to Predict Depression Treatment Response to Repetitive Transcranial Magnetic Stimulation (rTMS) in Patients With Major Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baptist Health South Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Florida International University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Baptist Health South Florida</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Repetitive Transcranial Magnetic Stimulation (rTMS) is a promising, novel, non-invasive&#xD;
      therapy for depression. The study is looking at changes in specific electroencephalogram&#xD;
      parameters in depressed patients treated with rTMS can serve as predictors of depression&#xD;
      treatment response among cancer patents undergoing rTMS treatment of depression.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be a prospective, single arm trial in which a set of patients who will be&#xD;
      treated for major depression using Repetitive Transcranial Magnetic Stimulation (according to&#xD;
      standard care) also will undergo EEG recording before Repetitive Transcranial Magnetic&#xD;
      Stimulation treatment begins, and at the completion of treatment. The Hamilton Depression&#xD;
      Rating Scale will be given to participants by the neuropsychiatrist at baseline and weekly&#xD;
      intervals till the completion of treatment.&#xD;
&#xD;
      The neuropsychiatrist investigators expect to see about 12 patients per year who meet&#xD;
      treatment criteria for Repetitive Transcranial Magnetic Stimulation. Therefore, it is&#xD;
      expected to recruit 24 subjects into the research study over a two-year period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    The investigators are in the process of transitioning the study site from one entity to another&#xD;
    within Baptist Health South Florida. As such, the study is suspended until the transition is&#xD;
    complete.&#xD;
  </why_stopped>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2031</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2030</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Hamilton Depression Rating Scale score</measure>
    <time_frame>baseline, and weekly until study completion, which can be up to 6 weeks</time_frame>
    <description>Hamilton Depression Rating Scale is used to measure severity of depression on a scale from 0 (no depression) to 52 (most severe depression).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Electroencephalograph (EEG) scalp signal changes over time</measure>
    <time_frame>baseline, end of treatment, which can be up to 6 weeks</time_frame>
    <description>Change in brain activity as measured by the EEG in microvolts.Scalp EEG signals will be processed in order to compare EEG brain connectivity and Frontal alpha asymmetry index (FAA).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Major Depression</condition>
  <condition>Repetitive Transcranial Magnetic Stimulation</condition>
  <arm_group>
    <arm_group_label>Electroencephalogram (EEG)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants will undergo EEG recording at baseline and end of treatment for a duration of 10-20 minutes per session.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Electroencephalogram (EEG)</intervention_name>
    <description>EEG measures brain activity by recording the spontaneous brain electrical activity and evoked responses non-invasively from the scalp. Reusable Tangle Free 10mm EEG Cup Electrodes will be placed on the subject's scalp using the 10-20 system montage.</description>
    <arm_group_label>Electroencephalogram (EEG)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosed with cancer&#xD;
&#xD;
          -  Comorbid diagnosis of major depressive disorder&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Baseline Hamilton Depression Rating Scale (HDRS) score ≥ 18&#xD;
&#xD;
          -  Failed one or more adequate antidepressant trials (including selective serotonin&#xD;
             reuptake inhibitors or SSRIs, selective norepinephrine reuptake inhibitors or SNRIs,&#xD;
             tricyclic antidepressants or TCAs). A failed treatment response may be due to lack of&#xD;
             antidepressant efficacy or intolerable side effects.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of seizure or epilepsy&#xD;
&#xD;
          -  History of concussion&#xD;
&#xD;
          -  History of bipolar disorder&#xD;
&#xD;
          -  Comorbid psychotic disorder&#xD;
&#xD;
          -  Primary brain tumor or metastasis to brain&#xD;
&#xD;
          -  Active comorbid substance use disorder&#xD;
&#xD;
          -  History or current diagnosis of dementia&#xD;
&#xD;
          -  Current pregnancy&#xD;
&#xD;
          -  Unable to attend regular treatment sessions&#xD;
&#xD;
          -  Any other condition in which a physician investigator feels may subject the&#xD;
             participant to undue risk&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Geetha Nampiaparampil, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Miami Cancer Institute (MCI) at Baptist Health, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Miami Neuroscience Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://neuroscience.baptisthealth.net/miami-neuroscience-institute</url>
    <description>Miami Neuroscience Institute</description>
  </link>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>September 22, 2020</study_first_submitted>
  <study_first_submitted_qc>September 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 5, 2020</study_first_posted>
  <last_update_submitted>August 30, 2021</last_update_submitted>
  <last_update_submitted_qc>August 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>rTMS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

